Insurance By Bob Herman Many Blue Cross Blue Shield plans aren’t paying taxes — and instead are swimming in refunds
Biotech By Jonathan Wosen ‘No real clear path’: Insurance coverage for cutting-edge diagnostics remains a major challenge for personalized medicine
Politics By Rachel Cohrs Biden administration favors insurers over doctors, hospitals in controversial new surprise billing regulations
Politics By Nicholas Florko and Ike Swetlitz Will Trump’s new drug rebates proposal end PBMs? And 6 other burning questions about the idea
Business By Kate Sheridan No products yet, but ambitious Atul Gawande health venture to begin ‘deploying tests’ this year
Business By Kate Sheridan and Casey Ross In a heated court hearing, Atul Gawande’s new company and Optum fight to keep their own secrets
The Pharmalot View By Ed Silverman This nonprofit is playing a valuable role in framing the drug price discussion
First Opinion By Yevgeniy Feyman and Austin Frakt Supreme Court delivers a blow to health care cost transparency